Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29216547 | 0.98 | PNMT (0.49) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL29507236 | 0.85 | PNMT (0.50) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL20425892 | 0.85 | PNMT (0.50) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL28591559 | 0.82 | PNMT (0.37) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL19684575 | 0.81 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL23735310 | 0.79 | PNMT (0.46) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL15778844 | 0.79 | PNMT (0.52) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL20892025 | 0.79 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL19684582 | 0.78 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL21237542 | 0.78 | PNMT (0.58) | PNMTASIC3ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| WO-2025049767-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-115073474-B | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | BEIGENE, LTD. (KY) | 2024-07-11 | — | — | US | disclosed |
| EP-4377318-A1 | PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043324-A | Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof | 百济神州有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023006063-A1 | PYRROLO [2, 3-b] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006063-A1 | PYRROLO [2, 3-b] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-02-02 | — | — | WO | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-115028639-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| EP-3994136-A1 | PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2022-05-11 | — | — | EP | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114096536-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113166139-A | Pyrrolo [2,3-b ] pyridines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | PDXK, STK25, STK35 | PNMT 3627/4885ASIC3 2484/4885ADRA2A 3644/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | PNMT 3627/4885ASIC3 2484/4885ADRA2A 3644/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885ASIC3 4751/4885ADRA2A 3923/4885 |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | HIPK1, MDM2, JMJD7 | PNMT 2985/4885ASIC3 4593/4885ADRA2A 4474/4885 |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | PNMT 2313/4885ASIC3 2392/4885ADRA2A 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.